Back to Results
First PageMeta Content
Ribbon symbolism / Trastuzumab / HER2/neu / Breast cancer / Genentech / Pertuzumab / Antibody-drug conjugate / Galena Biopharma / Lapatinib / Medicine / Chemistry / Oncology


Microsoft Word - 141219_MARIANNE unblinding_en
Add to Reading List

Document Date: 2014-12-19 01:00:00

Open Document

File Size: 114,82 KB

Share Result on Facebook

City

Basel / /

Company

ImmunoGen Inc. / Twitter / Genentech / Roche Group / Chugai Pharmaceutical / LinkedIn / Sandra F. Hoffmann-La Roche Ltd / /

Country

Switzerland / Japan / United States / /

Currency

CHF / /

/

Event

FDA Phase / Earnings Announcement / Business Partnership / /

/

IndustryTerm

research-focused healthcare / media relations / treatment of HER2-positive breast cancer / pharmaceuticals / diabetes management / /

MedicalCondition

tissue-based cancer / locally advanced disease / disease worsening / less aggressive HER2negative disease / HER2-positive cancers / thus preventing tumor / advanced breast cancer / breast cancer / tumor / previously treated disease / cancer / disease / HER2-positive cancer / both early and advanced HER2-positive disease / previously untreated advanced HER2-positive breast cancer / diabetes / infectious diseases / previously untreated disease / HER2-positive breast cancer / advanced HER2-positive breast cancer / /

MedicalTreatment

antibiotics / chemotherapy / investigational treatments / /

Organization

World Health Organization / Independent Review Committee / /

Person

Nicolas Dunant / Ulrike Engels-Lange / Nicole Rüppel / Nina Schwab-Hautzinger / Claudia Schmitt / Schwab-Hautzinger References / /

/

Position

Chief Medical Officer and Head of Global Product Development / leader / majority shareholder / Head / /

Product

Herceptin / paclitaxel / NCT01120184 / Kadcyla / /

Technology

neuroscience / in vitro diagnostics / chemotherapy / /

URL

www.roche.com/media/media_backgrounder/media_oncology.htm / www.linkedin.com/company/1602 / www.roche.com / /

SocialTag